{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '4.', 'Please sign below to confirm that you have completed this questionnaire.', 'Date:', '143']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix J.', 'Adverse Events Expected Due to SCLC or Progression of SCLC', 'Preferred Term (MedDRA Version 19.1)', 'Pleural effusion', 'Malignant pleural effusion', 'Metastases to pleura', 'Dyspnoea', 'Cough', 'Non-cardiac chest pain', 'Haemoptysis*', 'Oesophageal obstruction', 'Pneumonia*', 'Vocal cord paralysis', 'Dysphonia', 'Dysphagia', 'Superior vena cava syndrome', \"Horner's syndrome\", 'Myasthenic syndrome', 'Metastases to bone', 'Metastases to lymph nodes', 'Metastases to liver', 'Metastases to spine', 'Metastases to the mediastinum', 'Metastases to pleura', 'Metastases to adrenals', 'Metastases to meninges', 'Metastases to central nervous system', 'Cancer pain', 'Inappropriate Anti-Diuretic Hormone (SIADH) secretion', 'Tumour pain', 'Fatigue', 'Asthenia', 'Pulmonary embolism*', 'Shock*', 'Septic shock*', '144']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Preferred Term (MedDRA Version 19.1)', 'Deep vein thrombosis*', 'Lower respiratory tract infection*', 'Respiratory tract infection*', 'Upper respiratory tract infection*', 'Opportunistic infection*', 'Viral infection*', 'Fungal infection*', 'Bacterial infection*', 'Pulmonary haemorrhage*', 'Lung abscess*', 'Empyema*', 'Sepsis*', 'Lymphadenopathy', 'Decreased appetite', 'Malaise', 'Weight decreased', 'Headache', 'Pain excluding chest pain', 'Pyrexia', '*', 'Includes life threatening or fatal events.', '145']\n\n###\n\n", "completion": "END"}